Attentive Therapeutics
Michael Reilly has 30 years of international leadership experience in marketing, business development, finance, and strategy at Amgen, Baxter, Sanofi, and Sterling Drug.
He is a co-leader of 20 development teams in neuroscience and other therapeutic areas including the blockbuster denosumab valued over $11B and also a member of core team on acquisition of Immunex and Enbrel®, the largest in biotech history at $16B
Michael has a BA in Molecular Biology from the University of California, Berkeley & MBA from the University of Michigan, Ann Arbor.
This person is not in any offices
Attentive Therapeutics
1 followers
Developing new therapy that combines proven ADHD medications with an appetite stimulant. Recently successfully completed prospective clinical trial demonstrating highly significant impact on weight.